A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

NCT07034209 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophagocytic Lymphohistiocytoses

Interventions

DRUG: Plonmarlimab

Sponsor

TJ Biopharma Co., Ltd.